|
COVID-19 and Pulmonary Involvement |
|---|---|
| รหัสดีโอไอ | |
| Creator | Narongkorn Saiphoklang |
| Title | COVID-19 and Pulmonary Involvement |
| Contributor | Nuttapol Rittayamai |
| Publisher | Thammasat Printing House |
| Publication Year | 2564 |
| Journal Title | Asian Medical Journal and Alternative Medicine |
| Journal Vol. | 21 |
| Journal No. | Supplement 1 |
| Page no. | S81 |
| Keyword | Acute respiratory distress syndrome, COVID-19, Ground-glass opacity, Pneumonia |
| URL Website | http://asianmedjam.com/ |
| Website title | asianmedjam |
| ISSN | 2730-3578 |
| Abstract | The COVID-19 pandemic results in the largest global health crisis. Most patients are asymptomatic.Pneumonia usually develops in about one week after infection, with approximately 5% of patients needing ICU admission due to hypoxemia or acute respiratory failure. The common symptoms of patients with COVID-19 pneumonia are fever, cough, and sputum production. Typical radiographic features of pneumo-nia are bilateral lower lobe lesions with ground-glass opacities or consolidations. N95 respirator in com-bination with personal protective equipment are necessary to prevent COVID-19 from spreading among healthcare workers during aerosol-generating procedures. Hemodynamic and ventilation management of critically ill patients with COVID-19 should follow established guidelines. Remdesivir and dexamethasone are beneficial in hospitalized patients with COVID-19 pneumonia who require supplemental oxygen or mechanical ventilation. Favipiravir can reduce the duration of hospital stay and time for clinical treatment in hospitalized COVID-19 patients. Evidence regarding the benefits of other medications remains conflicting. |
